Literature DB >> 3181271

Experimental cancer therapy in mice by adenine nucleotides.

E Rapaport1.   

Abstract

Adenosine 5'-monophosphate (AMP), adenosine 5'-diphosphate (ADP) and adenosine 5'-triphosphate (ATP), injected intraperitoneally into tumor-bearing (s.c. implanted footpad tumors) mice, exhibited significant anticancer activity. Daily treatments (for 10 days) inhibited the growth of the fast-growing, aggressive CT 26 colon adenocarcinoma in CB6F1 mice. The growth-inhibitory activity of adenine nucleotides was also observed against a human pancreatic adenocarcinoma, CAPAN-1, xenografts in athymic nude mice. With low tumor burdens some 'cures' were obtained in both model systems. No inherent toxicity, as determined by changes in host weight, were observed during and after the period of treatment. Intraperitoneal injections of 1 ml of 50 mM AMP, ADP or ATP in saline, yielded elevated blood and plasma levels of ATP which lasted for several hours in both strains of mice. The growth-inhibitory activities of adenine nucleotides against tumor cells in vitro, have previously been demonstrated.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3181271     DOI: 10.1016/0277-5379(88)90340-9

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  17 in total

1.  Metabolic analysis of senescent human fibroblasts reveals a role for AMP in cellular senescence.

Authors:  Werner Zwerschke; Sybille Mazurek; Petra Stöckl; Eveline Hütter; Erich Eigenbrodt; Pidder Jansen-Dürr
Journal:  Biochem J       Date:  2003-12-01       Impact factor: 3.857

Review 2.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

Review 3.  Adenosine triphosphate: established and potential clinical applications.

Authors:  H J Agteresch; P C Dagnelie; J W van den Berg; J H Wilson
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

4.  Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate.

Authors:  Lili Feng; Xiaofeng Sun; Eva Csizmadia; Lihui Han; Shu Bian; Takashi Murakami; Xin Wang; Simon C Robson; Yan Wu
Journal:  Neoplasia       Date:  2011-03       Impact factor: 5.715

5.  Continuous intravenous infusion of ATP in humans yields large expansions of erythrocyte ATP pools but extracellular ATP pools are elevated only at the start followed by rapid declines.

Authors:  Eliezer Rapaport; Anna Salikhova; Edward H Abraham
Journal:  Purinergic Signal       Date:  2015-04-29       Impact factor: 3.765

Review 6.  Extracellular ATP and cancer: an overview with special reference to P2 purinergic receptors.

Authors:  Tamás Deli; László Csernoch
Journal:  Pathol Oncol Res       Date:  2008-06-25       Impact factor: 3.201

7.  Anticancer activities of adenine nucleotides in mice are mediated through expansion of erythrocyte ATP pools.

Authors:  E Rapaport; J Fontaine
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

8.  Inhibition of cancer growth and selective glutathione depletion in Ehrlich tumour cells in vivo by extracellular ATP.

Authors:  M C Lasso de la Vega; P Terradez; E Obrador; J Navarro; J A Pellicer; J M Estrela
Journal:  Biochem J       Date:  1994-02-15       Impact factor: 3.857

9.  An in vivo model of melanoma: treatment with ATP.

Authors:  Nicholas White; Gillian E Knight; Peter E M Butler; Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2009-04-04       Impact factor: 3.765

10.  Extracellular ATP and adenosine induce cell apoptosis of human hepatoma Li-7A cells via the A3 adenosine receptor.

Authors:  Long T Wen; Aileen F Knowles
Journal:  Br J Pharmacol       Date:  2003-10-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.